About

---

Vasculonics is developing novel selective aryl hydrocarbon receptor modulators (SAhRM) to override immune suppression and cancer immune evasion.  

•AhR stimulates IDO expression in cancer cells leading to generation of AhR activator Kyn.

•AhR induces PDL-1 and causes loss of effector function or exhaustion of CD8⁺ T-cells.

•AhR induces enrichment of Tregs in the tumor microenvironment which subsequently suppresses CD8+ T-cell proliferation and cytotoxicity.

•AhR modulates macrophage and dendritic cell activities.

Therefore, modulation of these AhR mediated immune suppressive activities by VN-1032 within the tumor microenvironment is a key strategy to enhance immunotherapy efficacy.

Vasculonics is developing novel selective aryl hydrocarbon receptor modulators (SAhRM) and suppressor of vascular toxin asymmetric dimethyl arginine (ADMA) the critical pathological mechanisms of PAH.  

AhR is known to play important pathological roles in inflammatory and fibrotic diseases. AhR activation has been found essential for PAH progression in humans and animal models.

VN-1032 is a novel selective AhR modulator (SAhRM) that targets key mechanisms underlying inflammation, oxidative stress, and fibrosis, demonstrating disease-modifying efficacy in preclinical models of pulmonary arterial hypertension (PAH) and chronic kidney disease (CKD) when administered orally.